Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01555463 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea
A Phase 3 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 961
- Enrollment target
NCT01555463 is a Phase 3 study that has completed, run by LEO Pharma. The registered enrollment target is 961 participants.
The verdict
NCT01555463, a Phase 3 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 961 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of azelaic acid (AzA) foam, 15% topically applied twice daily for 12 weeks in subjects with papulopustular rosacea compared to its vehicle.
Interventions
- DRUG Vehicle foam
- DRUG Azelaic acid foam, 15% (BAY39-6251)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 961 participants |
| Start Date | 2012-09 |
| Est. Completion | 2014-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01555463
The ClinicalTrials.gov registry entry for NCT01555463 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 961 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle foam is the first listed.
NCT01555463 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01555463 about?
NCT01555463 is a clinical study titled "Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea". The purpose of this study is to assess the safety and efficacy of azelaic acid (AzA) foam, 15% topically applied twice daily for 12 weeks in subjects with papulopustular rosacea compared to its vehicle.
What is the current status of trial NCT01555463?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 961 participants. The study started on 2012-09. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01555463?
The interventions under investigation include: Vehicle foam (DRUG), Azelaic acid foam, 15% (BAY39-6251) (DRUG).
Who is sponsoring clinical trial NCT01555463?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.